>_ QFI Terminal
Terminal › Stocks › FBRX

Forte Biosciences, Inc. (FBRX) Stock

Healthcare · Biotechnology · US
$76.50 +39.65%
Last updated Nov 12, 2026 10:46 UTC

FBRX Key Statistics

Market Cap$1.06B
P/E (TTM)-16.24
P/S (TTM)—
P/B (TTM)184.60
Revenue (TTM)$0.00
EPS (TTM)$-4.71
Dividend Yield—
ROE (TTM)-98.36%
Net Margin0.00%
Gross Margin0.00%
52W High$76.60
52W Low$15.51
Analyst ViewBuy
Price Target$65.00
Employees14
Volume17,108,344

About Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

CEO: Paul A. Wagner. Company website

FBRX — Frequently Asked Questions

What is the FBRX stock price today?

Forte Biosciences, Inc. (FBRX) trades at $76.50, up 39.65% on the day, as of Nov 12, 2026 10:46 UTC.

What is Forte Biosciences, Inc.'s market cap?

Forte Biosciences, Inc. has a market capitalisation of $1.06B, calculated from the live FBRX share price and shares outstanding.

What is the P/E ratio of FBRX?

FBRX has no meaningful price-to-earnings ratio: Forte Biosciences, Inc. lost $4.71 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Forte Biosciences, Inc. make?

Forte Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for FBRX?

FBRX has traded between $15.51 and $76.60 over the past 52 weeks, and the last price is 0.1% below that high.

Is Forte Biosciences, Inc. profitable?

Yes. Forte Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What is the analyst price target for FBRX?

Wall Street analysts rate FBRX Buy, with an average price target of $65.00, 15.0% below the current price.

What sector is Forte Biosciences, Inc. in?

Forte Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .

Who is the CEO of Forte Biosciences, Inc.?

Paul A. Wagner is the chief executive of Forte Biosciences, Inc., which employs 14 people.

Where can I track FBRX in real time?

QFI Terminal shows FBRX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See FBRX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open FBRX in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc ARGX argenx SE GMAB Genmab A/S NBIX Neurocrine Biosciences, Inc. BMRN BioMarin Pharmaceutical Inc. UTHR United Therapeutics Corporation CDT CDT Equity Inc. MRNA Moderna, Inc. EXEL Exelixis, Inc. BNTX BioNTech SE SRPT Sarepta Therapeutics, Inc. HALO Halozyme Therapeutics, Inc. INSM Insmed Incorporated MDGL Madrigal Pharmaceuticals, Inc. TECH Bio-Techne Corporation ASND Ascendis Pharma A/S CAI Caris Life Sciences, Inc. IONS Ionis Pharmaceuticals, Inc. BBIO BridgeBio Pharma, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. JNJ Johnson & Johnson LLY Eli Lilly and Company HCA HCA Healthcare, Inc. MRK Merck & Co., Inc. ABBV AbbVie Inc. PFE Pfizer Inc.